Xeris Biopharma Q2 net product revenue record $25.3M, reaffirms FY guidance

Xeris Biopharma Holdings, Inc.

2022-Q2 EPS reported -$0.44 revenue$47,379,000

Record Q2 net product revenue $25.3M, up 15% from Q1 and 34% pro forma YoY.
Gvoke net revenue $11.5M (+30% YoY); Keveyis $12.8M (+28% pro forma); Recorlev $1.0M.
Cash $111.6M at quarter-end; reaffirms FY net product revenue $105M-$120M, cash flow breakeven by end 2023.
Net loss $26.2M ($0.19/sh) in Q2, $59.9M ($0.44/sh) in H1.
Ogluo commercial partner Tetris Pharma acquired by Arecor Therapeutics in August 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.